Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2016 / Dec / Flesh or Blood
Liquid biopsy Profession Technology and innovation Screening and monitoring Professional Development

Flesh or Blood

Liquid biopsies offer a quick, non-invasive alternative to traditional techniques – and their use is growing

By William Aryitey 12/15/2016 1 min read

Share

Liquid biopsy – a phrase we’re hearing ever more frequently in pathology news. Headline-worthy for its ability to detect genetic material and cancers faster and more easily than conventional methods, liquid biopsy also carries the advantages of requiring only a simple blood draw rather than a sampling of tumor tissue. It’s certainly understandable why a technique that decreases the time pathologists spend performing tests – and, importantly, is far less invasive than a traditional tissue biopsy – would catch the attention of medical professionals and patients alike.

In spite of these seemingly convincing benefits, adoption of the technique has been slow – a hurdle an Australian research institute is hoping to overcome. The Olivia Newton-John Cancer Research Institute has become that first laboratory in Australia accredited by the National Association of Testing Authorities to implement the liquid biopsy technology, and for them, the method is already saving lives (1). But there are other factors encouraging the adoption of liquid biopsy too – like the various technologies being developed to boost its benefits. One example is droplet digital PCR (ddPCR), a technology that allows researchers to screen blood samples for tiny amounts of circulating DNA.

It’s already being used in the Australian lab to detect and analyze cancer genes, and its creators hope to see its popularity increase. Dawne Shelton, staff scientist at Bio-Rad Laboratories where the method was developed, says, “There are indications that liquid biopsies could help a wide variety of conditions. Data is being accumulated on autoimmune diseases and viral diseases, prenatal screening, and much more.” The aim is not for the technique to overtake existing methods, but to serve alongside them. “Liquid biopsies will never fully replace traditional biopsies,” says Shelton. “However, they will probably replace some of their uses, especially where invasive biopsies are particularly risky. New methods will evolve where more conventional methods are simply not acceptable, like in disease monitoring after treatment.”

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. Olivia Newton-John Cancer Wellness & Research Centre, “Melanoma blood test saves Lives”, (2016). Available at: http://bit.ly/2gb0H93. Accessed December 5, 2016.

About the Author(s)

William Aryitey

My fascination with science, gaming, and writing led to my studying biology at university, while simultaneously working as an online games journalist. After university, I travelled across Europe, working on a novel and developing a game, before finding my way to Texere. As Associate Editor, I’m evolving my loves of science and writing, while continuing to pursue my passion for gaming and creative writing in a personal capacity.

More Articles by William Aryitey

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

A Light in the Darkness
Liquid biopsy
A Light in the Darkness

March 4, 2022

2 min read

Spectroscopic liquid biopsy testing – a new route to brain cancer diagnostics

Biomarkers: The Bigger Picture
Liquid biopsy
Biomarkers: The Bigger Picture

April 27, 2022

1 min read

To unlock patient care, pathologists must focus on molecular pathology and ensure efficiency and effectiveness to improve testing. With this testing, patients can benefit from the best treatment to combat their disease.

Benchmarking… Liquid Biopsy
Liquid biopsy
Benchmarking… Liquid Biopsy

May 13, 2022

1 min read

A look at the last five years of publishing on liquid biopsy

Does Your Blood Know You Have Cancer?
Liquid biopsy
Does Your Blood Know You Have Cancer?

July 25, 2022

2 min read

Detection and monitoring are crucial for melanoma outcomes – could a blood test revolutionize both?

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.